Barclays’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $293K | Sell |
222,347
-249,761
| -53% | -$447K | ﹤0.01% | 3483 |
|
|
2025
Q4 | $883K | Buy |
472,108
+72,201
| +18% | +$139K | ﹤0.01% | 3522 |
|
|
2025
Q3 | $512K | Sell |
399,907
-90,185
| -18% | -$122K | ﹤0.01% | 3799 |
|
|
2025
Q2 | $608K | Buy |
490,092
+105,065
| +27% | +$121K | ﹤0.01% | 3650 |
|
|
2025
Q1 | $454K | Sell |
385,027
-1,275,032
| -77% | -$1.96M | ﹤0.01% | 3589 |
|
|
2024
Q4 | $3.04M | Buy |
1,660,059
+1,064,909
| +179% | +$2.08M | ﹤0.01% | 2574 |
|
|
2024
Q3 | $1.01M | Buy |
595,150
+350,196
| +143% | +$575K | ﹤0.01% | 3355 |
|
|
2024
Q2 | $336K | Sell |
244,954
-420,123
| -63% | -$848K | ﹤0.01% | 3277 |
|
|
2024
Q1 | $2.49M | Buy |
665,077
+199,227
| +43% | +$1.17M | ﹤0.01% | 2390 |
|
|
2023
Q4 | $4.57M | Buy |
465,850
+344,041
| +282% | +$2.81M | ﹤0.01% | 2175 |
|
|
2023
Q3 | $1.02M | Sell |
121,809
-189,547
| -61% | -$2.17M | ﹤0.01% | 2328 |
|
|
2023
Q2 | $4.14M | Buy |
311,356
+156,177
| +101% | +$1.9M | ﹤0.01% | 1456 |
|
|
2023
Q1 | $1.8M | Buy |
155,179
+28,211
| +22% | +$280K | ﹤0.01% | 2272 |
|
|
2022
Q4 | $1.04M | Buy |
126,968
+34,676
| +38% | +$299K | ﹤0.01% | 2762 |
|
|
2022
Q3 | $536K | Sell |
92,292
-87,032
| -49% | -$499K | ﹤0.01% | 2661 |
|
|
2022
Q2 | $792K | Buy |
179,324
+18,510
| +12% | +$112K | ﹤0.01% | 2536 |
|
|
2022
Q1 | $1.46M | Sell |
160,814
-157,996
| -50% | -$1.82M | ﹤0.01% | 2121 |
|
|
2021
Q4 | $6.52M | Buy |
318,810
+206,485
| +184% | +$4.98M | ﹤0.01% | 1526 |
|
|
2021
Q3 | $2.87M | Buy |
112,325
+53,157
| +90% | +$1.57M | ﹤0.01% | 2053 |
|
|
2021
Q2 | $2.07M | Sell |
59,168
-127,189
| -68% | -$3.7M | ﹤0.01% | 2167 |
|
|
2021
Q1 | $6.21M | Buy |
186,357
+127,143
| +215% | +$4.45M | ﹤0.01% | 1354 |
|
|
2020
Q4 | $1.53M | Sell |
59,214
-17,591
| -23% | -$299K | ﹤0.01% | 2454 |
|
|
2020
Q3 | $758K | Sell |
76,805
-48,125
| -39% | -$277K | ﹤0.01% | 2920 |
|
|
2020
Q2 | $431K | Buy |
124,930
+49,496
| +66% | +$169K | ﹤0.01% | 3456 |
|
|
2020
Q1 | $231K | Sell |
75,434
-679,483
| -90% | -$2.78M | ﹤0.01% | 4183 |
|
|
2019
Q4 | $3.88M | Buy |
754,917
+199,323
| +36% | +$1.01M | ﹤0.01% | 2289 |
|
|
2019
Q3 | $2.87M | Buy |
555,594
+267,982
| +93% | +$1.5M | ﹤0.01% | 2439 |
|
|
2019
Q2 | $1.74M | Sell |
287,612
-67,821
| -19% | -$476K | ﹤0.01% | 3088 |
|
|
2019
Q1 | $2.57M | Sell |
355,433
-243,122
| -41% | -$1.76M | ﹤0.01% | 2311 |
|
|
2018
Q4 | $4.43M | Buy |
598,555
+444,528
| +289% | +$2.82M | ﹤0.01% | 1680 |
|
|
2018
Q3 | $834K | Buy |
154,027
+104,955
| +214% | +$450K | ﹤0.01% | 3810 |
|
|
2018
Q2 | $173K | Buy |
49,072
+16,509
| +51% | +$45.8K | ﹤0.01% | 4842 |
|
|
2018
Q1 | $67K | Sell |
32,563
-69,675
| -68% | -$181K | ﹤0.01% | 5668 |
|
|
2017
Q4 | $270K | Buy |
102,238
+99,837
| +4,158% | +$350K | ﹤0.01% | 4430 |
|
|
2017
Q3 | $13K | Buy |
2,401
+1,755
| +272% | +$7.54K | ﹤0.01% | 6001 |
|
|
2017
Q2 | $2K | Sell |
646
-3,813
| -86% | -$15.4K | ﹤0.01% | 6433 |
|
|
2017
Q1 | $23K | Sell |
4,459
-27,153
| -86% | -$133K | ﹤0.01% | 5742 |
|
|
2016
Q4 | $120K | Sell |
31,612
-16,128
| -34% | -$117K | ﹤0.01% | 4623 |
|
|
2016
Q3 | $427K | Buy |
47,740
+46,624
| +4,178% | +$390K | ﹤0.01% | 3358 |
|
|
2016
Q2 | $7K | Sell |
1,116
-82,329
| -99% | -$752K | ﹤0.01% | 5659 |
|
|
2016
Q1 | $668K | Buy |
83,445
+37,065
| +80% | +$365K | ﹤0.01% | 2879 |
|
|
2015
Q4 | $603K | Buy |
46,380
+24,166
| +109% | +$217K | ﹤0.01% | 3066 |
|
|
2015
Q3 | $66K | Buy |
22,214
+20,969
| +1,684% | +$103K | ﹤0.01% | 4861 |
|
|
2015
Q2 | $6K | Sell |
1,245
-1,337
| -52% | -$7.74K | ﹤0.01% | 6362 |
|
|
2015
Q1 | $13K | Sell |
2,582
-5,794
| -69% | -$40K | ﹤0.01% | 6079 |
|
|
2014
Q4 | $59K | Sell |
8,376
-2,014
| -19% | -$12.9K | ﹤0.01% | 5592 |
|
|
2014
Q3 | $41K | Sell |
10,390
-16,634
| -62% | -$87K | ﹤0.01% | 6032 |
|
|
2014
Q2 | $162K | Buy |
27,024
+4,746
| +21% | +$23.8K | ﹤0.01% | 5015 |
|
|
2014
Q1 | $112K | Sell |
22,278
-4,667
| -17% | -$29.5K | ﹤0.01% | 5344 |
|
|
2013
Q4 | $135K | Buy |
26,945
+25,300
| +1,538% | +$116K | ﹤0.01% | 5375 |
|
|
2013
Q3 | $9K | Sell |
1,645
-33,936
| -95% | -$118K | ﹤0.01% | 6823 |
|
|
2013
Q2 | $90K | Buy |
+35,581
| New | +$88.6K | ﹤0.01% | 5868 |
|
Other funds holding PACB
AIM
VCM
NAMA
Barclays's PACB Position: Q1 2026 in Review
Barclays reduced its Pacific Biosciences (PACB) stake by 53% in Q1 2026, selling an estimated $447K and leaving 222,347 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #3483.
Barclays first reported a position in PACB in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.52M in Q4 2021. 230 funds tracked by Wall St. Rank hold PACB as of Q1 2026.
- Barclays held 222,347 shares of Pacific Biosciences worth $293K as of Q1 2026.
- Barclays sold 249,761 Pacific Biosciences shares in Q1 2026, an estimated $447K.
- Pacific Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3483 holding.
- Barclays first reported a position in Pacific Biosciences in Q2 2013 and has held it in 52 quarters since.
- Barclays's Pacific Biosciences position peaked at $6.52M in Q4 2021.
- 230 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.